Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(1):70-74; doi:10.1093/jnci/djh007
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (24)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Curtis, R. E.
Right arrow Articles by Fraumeni, J. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Curtis, R. E.
Right arrow Articles by Fraumeni, J. F., Jr.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

BRIEF COMMUNICATION

Risk of Malignant Mixed Mullerian Tumors After Tamoxifen Therapy for Breast Cancer

Rochelle E. Curtis, D. Michal Freedman, Mark E. Sherman, Joseph F. Fraumeni, Jr.

Affiliation of authors: Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD.

Correspondence to: Rochelle E. Curtis, MA, Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Executive Plaza South, Rm. 7042, Bethesda, MD 20892-7362 (e-mail: rcurtis{at}mail.nih.gov)

Recent studies have indicated that the tamoxifen-related risk of uterine corpus cancer may be especially high for some uncommon cell types, although the magnitude of risk has not been quantified. We evaluated data from 39 451 breast cancer patients diagnosed from 1980 through 2000 who were initially treated with tamoxifen and found that the overall risk of subsequent uterine corpus cancer was increased more than twofold (observed-to-expected ratio [O/E] = 2.17, 95% confidence interval [CI] = 1.95 to 2.41) relative to the general SEER population. The relative risk was substantially higher for malignant mixed mullerian tumors (MMMTs) (O/E = 4.62, O = 34, 95% CI = 3.20 to 6.46) than for endometrial adenocarcinomas (O/E = 2.07, O = 306, 95% CI = 1.85 to 2.32), although the excess absolute risk was smaller—an additional 1.4 versus 8.4 cancers per 10 000 women per year, respectively. Among those who survived for 5 years or longer, there was an eightfold relative risk for MMMTs and a 2.3-fold risk for endometrial adenocarcinomas, with patients developing MMMTs having a worse prognosis. These findings indicate that tamoxifen may have delayed effects, such as the increased risk of MMMTs, rare but aggressive tumors of unclear pathogenesis.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
L. J. Schild-Hay, T. A. Leil, R. L. Divi, O. A. Olivero, A. Weston, and M. C. Poirier
Tamoxifen Induces Expression of Immune Response-Related Genes in Cultured Normal Human Mammary Epithelial Cells
Cancer Res., February 1, 2009; 69(3): 1150 - 1155.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
S. Y. Teo, K. T. Babagbemi, H. E. Peters, and K. J. Mortele
Primary Malignant Mixed Mullerian Tumor of the Uterus: Findings on Sonography, CT, and Gadolinium-Enhanced MRI
Am. J. Roentgenol., July 1, 2008; 191(1): 278 - 283.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
W. Chu, A. Fyles, E. M. Sellers, D. R. McCready, J. Murphy, T. Pal, and S. A. Narod
Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use
Carcinogenesis, October 1, 2007; 28(10): 2139 - 2142.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. S. Spoelstra, N. G. Manning, Y. Higashi, D. Darling, M. Singh, K. R. Shroyer, R. R. Broaddus, K. B. Horwitz, and J. K. Richer
The Transcription Factor ZEB1 Is Aberrantly Expressed in Aggressive Uterine Cancers.
Cancer Res., April 1, 2006; 66(7): 3893 - 3902.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
L. A. Brinton, B. Scoccia, K. S. Moghissi, C. L. Westhoff, M. D. Althuis, and E. J. Lamb
Reply: Do drugs that stimulate ovulation increase the risk for endometrial stromal sarcoma?
Hum. Reprod., April 1, 2005; 20(4): 1112 - 1113.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
A. J. Swerdlow, M. E. Jones, and For the British Tamoxifen Second Cancer Study Grou
Tamoxifen Treatment for Breast Cancer and Risk of Endometrial Cancer: A Case-Control Study
J Natl Cancer Inst, March 2, 2005; 97(5): 375 - 384.
[Abstract] [Full Text] [PDF]

Home page
 MutagenesisHome page
L. J. Schild, D. H. Phillips, M. R. Osborne, A. Hewer, F. A. Beland, M. I. Churchwell, K. Brown, M. Gaskell, E. Wright, and M. C. Poirier
Hepatic DNA adduct dosimetry in rats fed tamoxifen: a comparison of methods
Mutagenesis, March 1, 2005; 20(2): 115 - 124.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
International Breast Cancer Study Group
Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93
Ann. Onc., December 1, 2004; 15(12): 1749 - 1759.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.